A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
Phase of Trial: Phase III
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Erdafitinib (Primary) ; Docetaxel; Pembrolizumab; Vinflunine
- Indications Carcinoma; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms THOR
- Sponsors Janssen; Janssen Research & Development; Janssen-Cilag
- 03 Apr 2019 Planned End Date changed from 1 Feb 2021 to 5 Nov 2021.
- 14 Nov 2018 Planned End Date changed from 30 Apr 2022 to 1 Feb 2021.
- 01 May 2018 Status changed from not yet recruiting to recruiting.